Landos Biopharma up 928% but really LABP fell 7% - one of those things

Landos Biopharma (NASDAQ: LABP) stock is up 928% by the usual measures. LABP is also down by 7% using the correct, and corrected, measure. In there is an important lesson for us. There's a difference between nominal prices and real prices. We must learn to grasp the difference between them. We saw this with inflation and the Marks & Spencer results. The results for that august retailer were regarded as good because there was growth in bottom lines sales and revenues. But after we'd adjusted for inflation real sales had actually fallen - which isn't such a good result for a retailer. Nominal prices and real prices, the difference between them, matters.

It's also possible for that difference to matter in a different way. As with this stock price at Landos Biopharma. As with many research pharma companies the stock price has dropped considerably over time: a 50% loss over the past 12 months for example. Well, that happens - we all know that research pharma is a very risky corner of the stock market. Many, even most, companies don't make it. It's the occasional one that does which makes up for all the rest. 

This though meets custom, fashion, on the American stock markets. There's an idea that a respectable company will have a price above $1. Anything less than this is, of course by definition, a penny stock. But that comes with insinuations of being fodder for people like the Wolf of Wall Street. Therefore a company with a price consistently below that $1 minimum bid price has to do something about it. Or, the alternative is to lose the NASDAQ quote. The problem there is that if you're relegated to the OTC it's much more difficult to raise new capital. But research pharma eats stockholder capital. So, something must be done. 

Landos Biopharma stock price from NASDAQ

That something is to have a reverse stock split - a consolidation to Brits. Simply declare that - say - what used to be 10 pieces of stock is now one piece of stock. The value of the company as a whole doesn't change, the value of any particular holding doesn't. All that changes is the number of pieces of paper that make up the company or any individual stake. Well, if that's so then the value of any individual share changes - it goes up by 1,000%, or 10x. Which is exactly what has happened at Landos Biopharma. They had a 10 for one share consolidation, reverse stock split, that kicked in Friday. Therefore the stock price should have risen 10x, or 1,000%. As we can see it actually rose by 928%. Which is less than 1,000%, in fact it's 7% less than that. 

So, Landos nominally rose by 928%, in real terms LABP fell by 7%. The difference between nominal and real prices is important.